Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic's board has approved a cash dividend of $0.68 per share for Q2 of fiscal year 2023, marking an 8% increase from the previous year. This dividend continues Medtronic's history as a member of the S&P 500 Dividend Aristocrats, having increased its dividend for 45 consecutive years. The dividend is set to be paid on October 14, 2022, to shareholders on record by September 23, 2022.
Medtronic plc (NYSE:MDT) will announce its financial results for the first quarter of fiscal year 2023 on August 23, 2022. The results will cover the period ending July 29, 2022, with a press release scheduled for 5:45 a.m. CDT. A video webcast discussing these results will follow at 7:00 a.m. CDT the same day. Future earnings reports are planned for November 22, 2022, February 21, 2023, and May 25, 2023.
Medtronic (NYSE:MDT) announces the expansion of its Health Equity Assistance Program for colon cancer screening, increasing the number of GI Genius™ units from 50 to 133 for underserved communities. The program aims to enhance screening access, starting with Grady Memorial Hospital in Atlanta, which serves a predominantly Black population. With a significant cancer burden in this community, the initiative hopes to improve early detection rates through advanced technology, further supported by Amazon Web Services.
Medtronic has secured FDA 510(k) clearance for its UNiD™ Spine Analyzer v4.0, which introduces a new Degen Algorithm for degenerative spine procedures. This innovative tool utilizes machine learning to aid surgeons in planning and personalizing surgeries, predicting post-operative spinal alignment six months post-surgery. The platform also features enhancements for both pediatric and adult deformity algorithms. Medtronic is the first to offer FDA-cleared predictive models for spine surgery, aiming to improve surgical outcomes significantly.
On July 12, 2022, Medtronic (NYSE:MDT) announced a strategic partnership with CathWorks, investing up to $75 million to co-promote the FFRangio® System in the U.S., Europe, and Japan. This non-invasive system utilizes artificial intelligence to enhance the diagnosis of coronary artery disease (CAD). Medtronic also has the option to acquire CathWorks for up to $585 million by July 2027. The partnership aims to revolutionize CAD management, with strong clinical evidence supporting FFRangio's 93% diagnostic accuracy.
Medtronic (NYSE: MDT) has appointed Lidia Fonseca as an independent director on its Board of Directors effective June 27, 2022. Fonseca, currently with Pfizer, brings over 30 years of experience in healthcare innovation, focusing on digital strategy and technology solutions. She will serve on the Compensation and Science and Technology Committees. Medtronic’s CEO, Geoff Martha, expressed enthusiasm, noting her expertise in digital healthcare solutions as crucial for the company’s ambition to lead in healthcare technology.
GE Healthcare and Medtronic announced the FDA 510(k) clearance and CE Mark approval for integrating their advanced Microstream™ capnography and INVOS™ regional oximetry technologies into the CARESCAPE precision monitoring platform. This collaboration aims to enhance patient outcomes by providing real-time, continuous monitoring, which helps in predicting and preventing perioperative complications. The integration supports improved clinical efficiency, safety, and quality of care, ultimately aiding clinicians in delivering personalized patient care.
Medtronic plc (NYSE:MDT) will participate in the Goldman Sachs Global Healthcare Conference on June 14, 2022. The session will be led by Geoff Martha, Medtronic's CEO, starting at 8:00 a.m. PDT. A live webcast will be accessible from the investor relations section of their website. Medtronic is a leader in healthcare technology, focusing on addressing critical health challenges globally. The company aims to alleviate pain, restore health, and extend life through innovative solutions, employing over 90,000 people worldwide.
Medtronic plc (NYSE: MDT) reported a 5% revenue growth for FY22, totaling $31.686 billion, with significant increases in GAAP diluted EPS of 40% to $3.73. Q4 revenue was $8.1 billion, down 1% due to supply chain issues and China’s COVID-19 lockdowns. Non-GAAP diluted EPS rose by 26% to $5.55. The company increased its quarterly dividend by 8% to $0.68 per share, marking 45 consecutive years of dividend growth. For FY23, Medtronic expects organic revenue growth of 4-5% and non-GAAP EPS between $5.53 and $5.65. Recent strategic partnerships aim to enhance product offerings in emerging markets.
Medtronic and DaVita are launching a new independent company focused on kidney care technology to enhance treatment experiences and patient outcomes. This collaboration aims to leverage Medtronic's healthcare technology skills and DaVita's expertise in kidney care to develop innovative products, including home-based dialysis solutions. Each company will hold equal stakes in the new entity, which will be governed by an independent management team. The transaction is expected to close within a year, pending regulatory approvals.